Show simple item record

dc.contributor.authorKjelby, Eirik
dc.contributor.authorJørgensen, Hugo A.
dc.contributor.authorKroken, Rune A.
dc.contributor.authorLøberg, Else-Marie
dc.contributor.authorJohnsen, Erik
dc.date.accessioned2012-01-23T10:05:18Z
dc.date.available2012-01-23T10:05:18Z
dc.date.issued2011-08-31eng
dc.identifier.citationBMC Psychiatry 2011, 11:145en
dc.identifier.issn1471-244X
dc.identifier.urihttp://hdl.handle.net/1956/5489
dc.description.abstractBackground: Efficacy studies indicate anti-depressive effects of at least some second generation antipsychotics (SGAs). The Bergen Psychosis Project (BPP) is a 24-month, pragmatic, industry-independent, randomized, head-tohead comparison of olanzapine, quetiapine, risperidone and ziprasidone in patients acutely admitted with psychosis. The aim of the study is to investigate whether differential anti-depressive effectiveness exists among SGAs in a clinically relevant sample of patients acutely admitted with psychosis. Methods: Adult patients acutely admitted to an emergency ward for psychosis were randomized to olanzapine, quetiapine, risperidone or ziprasidone and followed for up to 2 years. Participants were assessed repeatedly using the Positive and Negative Syndrome Scale - Depression factor (PANSS-D) and the Calgary Depression Scale for Schizophrenia (CDSS). Results: A total of 226 patients were included. A significant time-effect showing a steady decline in depressive symptoms in all medication groups was demonstrated. There were no substantial differences among the SGAs in reducing the PANSS-D score or the CDSS sum score. Separate analyses of groups with CDSS sum scores > 6 or ≤6, respectively, reflecting degree of depressive morbidity, revealed essentially identical results to the primary analyses. There was a high correlation between the PANSS-D and the CDSS sum score (r = 0.77; p < 0.01). Conclusions: There was no substantial difference in anti-depressive effectiveness among olanzapine, quetiapine, risperidone or ziprasidone in this clinically relevant sample of patients acutely admitted to hospital for symptoms of psychosis. Based on our findings we can make no recommendations concerning choice of any particular SGA for targeting symptoms of depression in a patient acutely admitted with psychosis.en_US
dc.language.isoengeng
dc.publisherBioMed Centraleng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/2.0/eng
dc.titleAnti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trialeng
dc.typePeer reviewed
dc.typeJournal article
dc.subject.nsiVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Pharmacology: 728eng
dc.subject.nsiVDP::Social science: 200::Psychology: 260eng
dc.description.versionpublishedVersion
dc.rights.holderCopyright 2011 Kjelby et al; licensee BioMed Central Ltd.
dc.identifier.doihttps://doi.org/10.1186/1471-244x-11-145
dc.identifier.cristin869642


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY